MK-3281 is a potent, orally bioavailable hepatitis C virus NS5B polymerase finger-loop inhibitor. It is also an inhibitor of attractive molecular properties with good potency in HCV subgenomic replication trials and suitable for clinical candidates.
Devazepide is a competitive and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor (IC50s: 81 pM, 45 pM, and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively).